Amgen Inc. $AMGN Stock Position Decreased by Ameriprise Financial Inc.

Ameriprise Financial Inc. decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 18.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,000,946 shares of the medical research company’s stock after selling 467,013 shares during the quarter. Ameriprise Financial Inc. owned approximately 0.37% of Amgen worth $563,848,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of AMGN. Evelyn Partners Investment Management LLP acquired a new stake in shares of Amgen in the 2nd quarter worth about $32,000. Howard Hughes Medical Institute bought a new position in Amgen in the 2nd quarter worth about $32,000. Cloud Capital Management LLC acquired a new stake in shares of Amgen in the third quarter valued at approximately $34,000. AXS Investments LLC acquired a new stake in shares of Amgen in the third quarter valued at approximately $42,000. Finally, Winnow Wealth LLC bought a new stake in shares of Amgen during the third quarter valued at approximately $47,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Performance

Shares of AMGN opened at $366.21 on Monday. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The firm’s 50 day moving average is $357.73 and its 200-day moving average is $325.68. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29. The stock has a market capitalization of $197.41 billion, a P/E ratio of 25.74, a P/E/G ratio of 3.63 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. During the same period in the previous year, the company posted $5.31 EPS. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is 70.84%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen will add medicines to the TrumpRx prescription site, which could expand patient access and volume for listed products if uptake follows; this is a near-term distribution win. GSK and Amgen to add medicines to TrumpRx, Fox Business reports
• Positive Sentiment: Product momentum — coverage highlights MariTide and osteoporosis treatments as sales drivers that have helped fuel recent rallies, supporting revenue growth expectations. Amgen: MariTide And Osteoporosis Sales Fuel The Rally
• Positive Sentiment: Institutional demand: Amgen is a notable holding in income-oriented funds, which supports steady shareholder demand given its long dividend track record. Starbucks, Amgen, and CVS Help This Income Fund Shine
• Positive Sentiment: Operational tie-ins: Rapid Micro Biosystems notes Amgen’s expansion of its Growth Direct system rollout — a small but constructive signal of ongoing manufacturing/capacity investments. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
• Neutral Sentiment: Analyst action: Jefferies issued a Hold on AMGN, a neutral rating that can dampen upside momentum vs. more bullish calls. Amgen (NASDAQ:AMGN) Earns Hold Rating from Analysts at Jefferies Financial Group
• Neutral Sentiment: Press roundups: Amgen appears in broader mega-cap watchlists and industry write-ups — visibility is high but these pieces are more contextual than catalytic. 2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds
• Negative Sentiment: Dividend/valuation concerns: Independent analysis flags high debt levels, weaker risk-adjusted returns and questions around dividend attractiveness at current prices — these are potential longer‑term headwinds for the stock’s re-rating. Dividend Stock Analysis – Amgen, Inc.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on AMGN shares. Piper Sandler increased their price objective on Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Guggenheim boosted their price target on Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. Truist Financial increased their price target on Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research note on Thursday, January 8th. Royal Bank Of Canada raised their price target on Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a report on Wednesday, February 4th. Finally, Cantor Fitzgerald upped their price objective on shares of Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $354.00.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.